MicroRNA and Cancer
MicroRNAs (miRs) are small noncoding RNAs that function as post-transcriptional regulators of gene expression and have important roles in almost all biological pathways. Deregulated miR expression has been detected in numerous cancers, where miRs act as both oncogene and tumor suppressors. Due to th...
Kaydedildi:
| Diğer Yazarlar: | |
|---|---|
| Materyal Türü: | Elektronik Kitap Bölümü |
| Dil: | İngilizce |
| Baskı/Yayın Bilgisi: |
Basel
MDPI - Multidisciplinary Digital Publishing Institute
2022
|
| Konular: | |
| Online Erişim: | DOAB: download the publication DOAB: description of the publication |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|
MARC
| LEADER | 00000naaaa2200000uu 4500 | ||
|---|---|---|---|
| 001 | doab_20_500_12854_87433 | ||
| 005 | 20220706 | ||
| 003 | oapen | ||
| 006 | m o d | ||
| 007 | cr|mn|---annan | ||
| 008 | 20220706s2022 xx |||||o ||| 0|eng d | ||
| 020 | |a books978-3-0365-4415-1 | ||
| 020 | |a 9783036544168 | ||
| 020 | |a 9783036544151 | ||
| 040 | |a oapen |c oapen | ||
| 024 | 7 | |a 10.3390/books978-3-0365-4415-1 |c doi | |
| 041 | 0 | |a eng | |
| 042 | |a dc | ||
| 072 | 7 | |a GP |2 bicssc | |
| 072 | 7 | |a PS |2 bicssc | |
| 100 | 1 | |a Tucci, Paola |4 edt | |
| 700 | 1 | |a Tucci, Paola |4 oth | |
| 245 | 1 | 0 | |a MicroRNA and Cancer |
| 260 | |a Basel |b MDPI - Multidisciplinary Digital Publishing Institute |c 2022 | ||
| 300 | |a 1 electronic resource (298 p.) | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 506 | 0 | |a Open Access |2 star |f Unrestricted online access | |
| 520 | |a MicroRNAs (miRs) are small noncoding RNAs that function as post-transcriptional regulators of gene expression and have important roles in almost all biological pathways. Deregulated miR expression has been detected in numerous cancers, where miRs act as both oncogene and tumor suppressors. Due to their important roles in tumorigenesis, miRs have been investigated as prognostic and diagnostic biomarkers and as useful targets for therapeutic intervention. From a therapeutic point of view, two modalities can serve to rectify gene networks in cancer cells. For oncomiRs, a rational means is downregulation through antagomirs. Moreover, observations of the pathological reductions in tumor-suppressive miRs have inspired the concept of "miR replacement therapy" to enhance the amount of these miRs, thereby restoring them to normal levels. However, the clinical applicability of miR-based therapies is severely limited by the lack of effective delivery systems. Therefore, to understand the role of this new class of regulators, we need to identify the mRNA targets regulated by individual miRs as well as to develop specific, efficient, and safe delivery systems for therapeutic miRs. | ||
| 540 | |a Creative Commons |f https://creativecommons.org/licenses/by/4.0/ |2 cc |4 https://creativecommons.org/licenses/by/4.0/ | ||
| 546 | |a English | ||
| 650 | 7 | |a Research & information: general |2 bicssc | |
| 650 | 7 | |a Biology, life sciences |2 bicssc | |
| 653 | |a Breast cancer | ||
| 653 | |a Hypoxia inducible factor 1-alpha (HIF-1α) | ||
| 653 | |a MicroRNA (miRNA) | ||
| 653 | |a miR526b | ||
| 653 | |a miR655 | ||
| 653 | |a Oxidative stress | ||
| 653 | |a Migration | ||
| 653 | |a Cyclooxygenase-2 (COX-2) | ||
| 653 | |a Prostaglandin E2 receptor 4 (EP4) | ||
| 653 | |a PI3K/Akt | ||
| 653 | |a adipokines | ||
| 653 | |a endometrial cancer | ||
| 653 | |a estrogens | ||
| 653 | |a hyperinsulinemia | ||
| 653 | |a insulin | ||
| 653 | |a insulin resistance | ||
| 653 | |a insulin signaling | ||
| 653 | |a insulin-like growth factors | ||
| 653 | |a microRNA | ||
| 653 | |a miRNA | ||
| 653 | |a ovarian cancer | ||
| 653 | |a survival | ||
| 653 | |a prognostic factor | ||
| 653 | |a serum LDH | ||
| 653 | |a blood biomarker | ||
| 653 | |a circulating microRNA | ||
| 653 | |a plasma | ||
| 653 | |a immunotherapy | ||
| 653 | |a immune checkpoint inhibitors | ||
| 653 | |a metastatic melanoma | ||
| 653 | |a hepatocellular carcinoma | ||
| 653 | |a metastasis | ||
| 653 | |a exosome | ||
| 653 | |a bioinformatics analysis | ||
| 653 | |a renal cancer | ||
| 653 | |a RCC | ||
| 653 | |a ccRCC | ||
| 653 | |a meta-analysis | ||
| 653 | |a miRNAs | ||
| 653 | |a normal B-cell development | ||
| 653 | |a B-CLL | ||
| 653 | |a miRNA-transcription factor network | ||
| 653 | |a regulation | ||
| 653 | |a biomarker | ||
| 653 | |a therapy | ||
| 653 | |a prognosis | ||
| 653 | |a diagnosis | ||
| 653 | |a progression | ||
| 653 | |a prediction | ||
| 653 | |a smoking | ||
| 653 | |a non-small cell lung cancer | ||
| 653 | |a methylation | ||
| 653 | |a miR-584-5p | ||
| 653 | |a YKT6 | ||
| 653 | |a snoRNA | ||
| 653 | |a 2'-O-methylation | ||
| 653 | |a pseudouridylation | ||
| 653 | |a malignant melanoma | ||
| 653 | |a cancer stem cell | ||
| 653 | |a stemness | ||
| 653 | |a head and neck squamous cell carcinoma | ||
| 653 | |a colon cancer | ||
| 653 | |a cancer stem cells | ||
| 653 | |a microRNAs | ||
| 653 | |a deformability | ||
| 653 | |a PARP | ||
| 653 | |a replication stress | ||
| 653 | |a targeted therapy | ||
| 653 | |a breast cancer | ||
| 653 | |a circulating biomarkers | ||
| 653 | |a medulloblastoma | ||
| 653 | |a brain tumour | ||
| 653 | |a subgroups | ||
| 653 | |a stem cells | ||
| 653 | |a n/a | ||
| 856 | 4 | 0 | |a www.oapen.org |u https://mdpi.com/books/pdfview/book/5621 |7 0 |z DOAB: download the publication |
| 856 | 4 | 0 | |a www.oapen.org |u https://directory.doabooks.org/handle/20.500.12854/87433 |7 0 |z DOAB: description of the publication |